Investing.com - Zealand Pharma (NASDAQ:ZEAL) ADR reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Zealand Pharma ADR announced earnings per share of $-0.25 on revenue of $35.04M. Analysts polled by Investing.com anticipated EPS of $-0.26 on revenue of $29.62M.
Zealand Pharma ADR shares are up 14.61% from the beginning of the year, still down 14.69% from its 52 week high of $44.60 set on February 14. They are under-performing the Nasdaq which is up 23.07% from the start of the year.
Zealand Pharma ADR follows other major sector earnings this month
Zealand Pharma ADR's report follows an earnings beat by Tencent ADR on Wednesday, who reported EPS of $0.49 on revenue of $16.54B, compared to forecasts EPS of $0.41 on revenue of $16.04B.
L’Oreal ADR had beat expectations on July 30 with second quarter EPS of $3.82 on revenue of $6.92B, compared to forecast for EPS of $0.85 on revenue of $6.98B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar